

-continued

```

<210> SEQ ID NO 129
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Kabat Defined Mov19 HC CDR2 Human

```

```

<400> SEQUENCE: 129

```

```

Arg Ile His Pro Tyr Asp Gly Asp Thr Phe Tyr Asn Gln Lys Phe Gln
1           5              10              15

```

```

Gly

```

```

<210> SEQ ID NO 130
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: muFR1-49 Kabat defined HC CDR2

```

```

<400> SEQUENCE: 130

```

```

Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Leu Lys Phe Lys
1           5              10              15

```

```

Gly

```

```

<210> SEQ ID NO 131
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: huMov19 vHC CDR2

```

```

<400> SEQUENCE: 131

```

```

Arg Ile His Pro Tyr Asp Gly Asp Thr Phe
1           5              10

```

1.-127. (canceled)

128. An immunoconjugate comprising the formula (A)-(L)-(C), wherein:

(A) is an antibody or antigen binding fragment thereof that specifically binds a human folate receptor 1;

(L) is a linker; and

(C) is a cytotoxic agent;

wherein (L) links (A) to (C); and

wherein the antibody or antigen binding fragment thereof comprises:

a heavy chain CDR1 comprising the amino acid sequence of GYFMN (SEQ ID NO:1), a heavy chain CDR2 comprising the amino acid sequence of RIHPYDGDTF (SEQ ID NO:131), and a heavy chain CDR3 comprising the amino acid sequence of YDGSRAMDY (SEQ ID NO:3); and

a light chain CDR1 comprising the amino acid sequence of KASQSVSFAGTSLMH (SEQ ID NO:7), a light chain CDR2 comprising the amino acid sequence of RASNLEA (SEQ ID NO:8), and a light chain CDR3 comprising the amino acid sequence of QQSREYPYT (SEQ ID NO:9).

129. The immunoconjugate of claim **128**, wherein (L) is a linker selected from the group consisting of: a non-cleavable linker, a hydrophilic linker, and a dicarboxylic acid based linker.

130. The immunoconjugate of claim **128**, wherein the linker is selected from the group consisting of: N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC); N-sulfosuccinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (sulfoSMCC); N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB); and N-succinimidyl-[(N-maleimidopropionamido)-tetraethyleneglycol] ester (NHS-PEG4-maleimide).

131. The immunoconjugate of claim **128**, wherein (L) is a cleavable linker.

132. The immunoconjugate of claim **131**, wherein the linker is selected from the group consisting of: N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP); N-succinimidyl 4-(2-pyridyldithio)-2-sulfopentanoate (sulfo-SPP); N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB); and N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB).

133. The immunoconjugate of claim **128**, wherein the cytotoxic agent is selected from the group consisting of: a maytansinoid, maytansinoid analog, benzodiazepine, taxoid, CC-1065, CC-1065 analog, duocarmycin, duocarmycin ana-